HeartSciences Inc Dossier - Source-backed chat

HeartSciences Inc

HSCSNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)1.50

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $3.89Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $18.8M

Enterprise Value $22.4M

Shares Outstanding 4.8M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

HeartSciences Inc. (Nasdaq: HSCS) is transitioning from a clinical-stage medical technology developer to a commercial-scale SaaS and hardware-agnostic AI-ECG platform provider. The company's MyoVista Insights platform and its proprietary MyoVista wavECG device address a massive $30 billion global ECG market. With the MyoVista wavECG device submitted for FDA 510(k) clearance in December 2025 and the MyoVista Insights platform already generating initial SaaS revenues, the company is poised for a significant valuation re-rating. Furthermore, the established CMS reimbursement rate of approximately $125-$128 per test for AI-ECG algorithms starting in 2025 provides a highly lucrative and clear path to monetization.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$8.00

Mean target$10.00

High · most bullish analyst$12.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.9020%

Regulatory delays in securing FDA 510(k) clearances push commercialization timelines into late 2027 or beyond. Continued high cash burn (approximately $9 million annually) in the absence of meaningful revenues forces highly dilutive equity financing rounds or raises going-concern risks, severely depressing the stock price.

Base CaseCentral scenario

$9.2050%

HeartSciences successfully secures FDA clearance for the MyoVista wavECG device in late 2026. Commercial execution proceeds steadily with initial hospital deployments, such as the Cibolo Health Network, translating into growing recurring SaaS revenues. The company manages its capital requirements through controlled equity raises or strategic partnerships, gradually expanding its AI-ECG marketplace.

Bull CaseUpside scenario

$12.0030%

Rapid FDA 510(k) clearance of the MyoVista wavECG device and the low ejection fraction algorithm in 2026 triggers widespread clinical adoption. Integration with major EHR systems via the Epic Toolbox Designation accelerates hospital deployments. The company scales rapidly through its high-margin, asset-light SaaS marketplace model, hosting both proprietary and third-party algorithms, driving exponential revenue growth and achieving profitability ahead of consensus expectations.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-mover advantage in AI-ECG with a robust intellectual property portfolio of over 45 granted patents.
Asset-light, highly scalable business model centered around the hardware-agnostic MyoVista Insights SaaS platform and AI marketplace.
Favorable reimbursement environment with established CMS Medicare/Medicaid reimbursement of ~$125-$128 per AI-ECG test.
Strategic partnerships and integrations, including Epic Toolbox Designation and commercial agreements with networks like Cibolo Health.

Key Investment Risks

High regulatory dependency on pending FDA 510(k) clearances for core devices and algorithms.
Pre-revenue financial profile with a history of net losses and reliance on external capital raises to fund operations.
Risk of shareholder dilution due to future equity offerings required to support commercial launch and working capital.
Nasdaq listing compliance risks related to minimum stockholders' equity requirements.

Thesis Invalidation Triggers

FDA rejection or prolonged delay of the MyoVista wavECG 510(k) submission.
Inability to secure additional financing, leading to a severe liquidity crisis or going-concern failure.
Failure to gain commercial traction or generate meaningful SaaS revenues from early-adopter deployments.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.